Skip to content

Merck, Novo Nordisk Spared From 1,500 Suits Over Diabetes Drug Blamed for Cancer

  • Email shows lawyers plan to drop lawsuits against companies
  • Ruling barring pancreatic cancer testimony prompted decision
Signage outside Merck & Co. headquarters in Kenilworth, New Jersey.

Signage outside Merck & Co. headquarters in Kenilworth, New Jersey.

Photographer: Christopher Occhicone/Bloomberg

Consumers suing Merck & Co., Novo Nordisk A/S and other makers of diabetes drugs allegedly linked to pancreatic cancer are dropping their complaints, according to an email seen by Bloomberg.

The decision, revealed in an email to clients from an attorney involved in the litigation, will spare the company from facing more than 1,500 lawsuits. It comes after a judge last year barred the plaintiffs’ experts from testifying about any cancer link, a ruling that was upheld on appeal late last month.